A generic version of levetiracetam, previously only available as brand-name Keppra from UCB Pharma, has been released by Mylan Pharmaceuticals in a generic form. Mylan announced on 11/4/2008 that the United States Food and Drug Administration (FDA) approved generic versions of levetiracetam in 250, 500 and 750 mg sizes. Generic medications typically cost less than do brand-name medications. The FDA requires the generic medication produce bloodstream levels in the range of 80-125% of the level produced by the comparable brand-name medication. According to Mylan's press release, levetiracetam sales in the United States were approximately $1 billion for the year ending 9/30/08. Individual pharmacies may require weeks or a few months to receive and stock generic levetiracetam.